In one paragraphArticle in Journal of Alzheimer's disease : JAD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Kyle J EdmundsDepartment of Medicine and Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID 0000-0002-6591-4116 Alexis R NelsonDepartment of Medicine and Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID 0009-0009-5414-2913 Talia L BrachDepartment of Medicine and Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Matthew GlittenbergDepartment of Medicine and Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID 0009-0002-9152-4637 Bradley T ChristianDepartment of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Tobey J BetthauserDepartment of Medicine and Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID 0000-0001-8856-1352 Sterling C JohnsonDepartment of Medicine and Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Sanjay AsthanaDepartment of Medicine and Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Ozioma C OkonkwoDepartment of Medicine and Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Funding
Wisconsin Registry for Alzheimer's PreventionR01AG027161 · UNIVERSITY OF WISCONSIN-MADISON · 2025 to 2025
$5.7MAfrican Americans Fighting Alzheimer’s in Midlife (AA-FAIM)R01AG054059 · NIA · UNIVERSITY OF WISCONSIN-MADISON · 2024 to 2025
$5.3MWisconsin Alzheimer's Disease Research CenterP30AG062715 · UNIVERSITY OF WISCONSIN-MADISON · 2025 to 2025
$4.4MLongitudinal Investigation of Cardiorespiratory Fitness and AD Biomarkers in an At-Risk CohortR01AG062167 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Ozioma C Okonkwo · 2021 to 2023
$2.8MWaisman Center Intellectual and Developmental Disabilities Research CenterP50HD105353 · UNIVERSITY OF WISCONSIN-MADISON · 2025 to 2025
$1.2MKLOTHO and Resilience to Synaptic Dysfunction in Preclinical ADR01AG077507 · UNIVERSITY OF WISCONSIN-MADISON · 2025 to 2025
$756kNCRR NIH HHS UL1 RR025011NIA NIH HHS P30 AG062715NIA NIH HHS R01 AG027161NIA NIH HHS R01 AG054059NIA NIH HHS R01 AG062167NIA NIH HHS R01 AG077507NICHD NIH HHS P50 HD105353NIH HHS S10 OD030415
6 · The paper itselfAbstract
BackgroundDepression-especially late-life onset-is associated with age-related cognitive decline and may be a key risk factor for amyloid-β (Aβ) deposition in preclinical Alzheimer's disease (AD).ObjectiveThis study assesses whether depressive symptoms modify the relationship between age and Aβ burden in a cohort at-risk for AD.MethodsN = 238 cognitively unimpaired participants from the Wisconsin Alzheimer's Disease Research Center participated in Pittsburgh Compound-B positron emission tomography (
Indexed as
AgingAlzheimer DiseaseAmyloid beta-PeptidesBrainDepressionAgedAged, 80 and overAniline CompoundsApolipoprotein E4Carbon RadioisotopesCohort StudiesCross-Sectional StudiesFemaleHumansMaleMiddle Aged2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazoleAmyloid beta-PeptidesAniline CompoundsApolipoprotein E4Carbon RadioisotopesThiazoles[11C]PiB-PET imagingagingAlzheimer's diseaseamyloid-βgeriatric depression
Identifiers
PMID40635663
PMCPMC13101852
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390